MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, IKNA had $18,897K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$18,897K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-06-30
Stock-based compensation expense
1,362
Net loss
-11,386
Non-cash operating lease expense
1,074
Prepaid expenses and other current assets
588
Other long-term liabilities
31
Operating lease liabilities
-1,844
Deposits and other assets
-940
Accrued expenses and other current liabilities
-3,119
Accounts payable
-385
Impairment of assets held for sale
0
Loss on disposal of property and equipment
0
Depreciation
174
Net accretion of discounts on marketable securities
243
Net cash used in operating activities
-13,984
Proceeds from sale of property and equipment
0
Proceeds from sales and maturities of marketable securities
71,065
Purchases of marketable securities
23,184
Amounts loaned under note receivable
15,000
Net cash provided by (used in) investing activities
32,881
Net increase (decrease) in cash, cash equivalents and restricted cash
18,897
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Ikena Oncology, Inc. (IKNA)

Ikena Oncology, Inc. (IKNA)